Apontis Pharma AG (XTER:APPH) Cash-to-Debt : 4.45 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Apontis Pharma AG Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Apontis Pharma AG's cash to debt ratio for the quarter that ended in Dec. 2023 was 4.45.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Apontis Pharma AG could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Apontis Pharma AG's Cash-to-Debt or its related term are showing as below:

XTER:APPH' s Cash-to-Debt Range Over the Past 10 Years
Min: 4.45 Med: No Debt Max: No Debt
Current: 4.45

During the past 6 years, Apontis Pharma AG's highest Cash to Debt Ratio was No Debt. The lowest was 4.45. And the median was No Debt.

XTER:APPH's Cash-to-Debt is ranked better than
69.36% of 1051 companies
in the Drug Manufacturers industry
Industry Median: 0.93 vs XTER:APPH: 4.45

Apontis Pharma AG Cash-to-Debt Historical Data

The historical data trend for Apontis Pharma AG's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Apontis Pharma AG Cash-to-Debt Chart

Apontis Pharma AG Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

4.45

Apontis Pharma AG Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial				No Debt	No Debt	No Debt	No Debt	4.45

Competitive Comparison of Apontis Pharma AG's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Apontis Pharma AG's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Apontis Pharma AG's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Apontis Pharma AG's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Apontis Pharma AG's Cash-to-Debt falls into.

Apontis Pharma AG Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Apontis Pharma AG's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	26.816	/	(6.02	+	0)
	=	4.45

Apontis Pharma AG's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	26.816	/	(6.02	+	0)
	=	4.45

Apontis Pharma AG (XTER:APPH) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Apontis Pharma AG Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Apontis Pharma AG's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Apontis Pharma AG (XTER:APPH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Apontis Pharma AG (XTER:APPH) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

Alfred-Nobel-Strabe 10, Monheim, BY, DEU, 40789

Website

https://www.apontis-pharma.de

Apontis Pharma AG is a pharmaceutical company specializing in single pills in Germany. single pills combine two to three generic active ingredients in a single dosage form. The company develops, promotes, and sells a broad portfolio of single pills and other pharmaceutical products, with a special focus on cardiovascular diseases.

Executives

Karlheinz Gast	Board of Directors
Thomas Milz	Board of Directors

Apontis Pharma AG (XTER:APPH) Headlines

No Headlines